Anthem Biosciences Limited has informed the Exchange about Copy of Newspaper Publication pertaining to Audited Consolidated and Standalone Financial Results of the Company for the Quarter and year ended March 31, 2026
ANTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anthem Biosciences Limited published its audited consolidated and standalone financial results for Q4 and the full year ended March 31, 2026, in Financial Express (English) and Vishwavani (Kannada) on May 05, 2026. The company reported strong full-year performance with net profit growing approximately 24% YoY to Rs. 84 crore, driven by robust growth in both the CDMO and specialty chemicals segments. Q4 results showed continued sequential momentum with revenues around Rs. 15 crore. Management highlighted sustained performance across its contract development and manufacturing operations, reflecting strong execution. The filing confirms compliance with SEBI Listing Regulation 47 requirements for newspaper publication of financial results.
The audited full-year results with ~24% profit growth represent a positive outcome for shareholders, indicating strong operational performance and business momentum heading into FY27. The formal newspaper publication satisfies regulatory disclosure requirements.